RxDoctor Payments DataLook up a doctor →

Michael Meshad, MD

Hematology & Oncology · Mobile, ALNPI 1538112701

Payments from drug & device makers

$5,313,258in general payments, 2019–2025

Across 2,399 payments — averaging $2214.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$1M
  • Eli Lilly$869K
  • Amgen$534K
  • AstraZeneca$493K
  • Genentech, Inc.$481K
  • Merck$440K
  • plus $1.5M from 54 others
$10,032in research payments, 2019–2025

Across 13 payments — averaging $771.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Scientific Affairs, LLC$10K
  • Eli Lilly$32

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.100$1,021,393
Eli Lilly35$868,796
Amgen46$534,278
AstraZeneca(2 entities)55$493,195
Genentech, Inc.165$481,066
Merck242$440,374
Janssen Research & Development, LLC209$293,198
Daiichi Sankyo Inc.262$231,089
Pharmacyclics LLC, An Abbvie Company145$169,881
Pfizer92$156,649
Novartis100$127,857
Puma Biotechnology, Inc.62$127,495
Epizyme, Inc.44$68,648
Sanofi US Services Inc.37$62,571
Takeda Pharmaceuticals U.S.A., Inc.42$59,716
Mirati Therapeutics, Inc.81$45,020
Incyte Corporation76$29,839
Morphosys AG29$25,761
AbbVie31$19,686
F. Hoffmann-la Roche AG3$15,072
Janssen Scientific Affairs, LLC143$10,937
Gilead(2 entities)17$8,156
Lilly USA, LLC15$6,906
Beigene, Ltd.3$4,500
Immunomedics, Inc.1$2,667
Astellas Pharma US Inc53$1,001
Morphosys, US Inc.1$956
Bristol Myers Squibb33$788
Macrogenics, Inc.1$615
Genentech USA, Inc.31$592
Johnson & Johnson34$584
Regeneron Healthcare Solutions, Inc.16$394
Eisai Inc.21$394
Sanofi13$254
Array Biopharma Inc12$212
GSK11$187
Ipsen Biopharmaceuticals, Inc8$183
Boehringer Ingelheim8$173
Deciphera Pharmaceuticals Inc.8$142
Beigene USA, Inc.10$134
Springworks Therapeutics, Inc.7$118
Seagen Inc.7$107
Stemline Therapeutics Inc.5$107
Sanofi-aventis U.S. LLC1$100
Karyopharm Therapeutics Inc.6$97
EMD Serono, Inc.6$90
Coherus Oncology, Inc.4$75
Blueprint Medicines Corporation3$67
Servier Pharmaceuticals LLC4$63
Exelixis Inc.3$56
Octapharma USA, Inc.3$55
G1 Therapeutics, Inc.3$52
Acceleron Pharma, Inc.3$52
Dova Pharmaceuticals3$49
Acrotech Biopharma Inc.3$49
Tersera Therapeutics LLC2$49
Progenics Pharmaceuticals, Inc.2$41
Heron Therapeutics, Inc.1$41
ADC Therapeutics America, Inc.2$41
Tesaro, Inc.2$40

How this compares

$5,313,258 in reported general payments places this provider in the 95th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama →

Medicare billing

Part B allowed, 2024
$3,330,239
Medicare patients
468
Services billed
104,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Mobile

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →